44 results about "Endometrial hyperplasia" patented technology

The invention discloses a minorcaliber tissue engineering artificial vessel. The excised extract cell umbilical vessel is taken as a bracket, the gap part of the bracket is filled with smooth muscle cells and mechanocyte; the endothelial progenitor cells or mesenchymal stem cells are planted in the surface of the inner wall of the excised extract cell umbilical vessel. The minorcaliber tissue engineering artificial vessel has good biocompatibility and has the abilities of inducing, supporting and maintaining cell functions, thus reducing the reciprocal infection of virus among seeds. The artificial vessel produced by the invention overcomes the problem that the supply of autologous vessel plantation is limited and the failure problem of the synthesized implants for formation of thrombosisand / or endometrial hyperplasia, thus improving the long transplantation patency that the minorcaliber tissue engineering artificial vessel is planted into human body, leading the sufferers to avoid asecondary operation. The raw materials of the artificial vessel are obtained easily, the preparation method is simple, and cost is low, thus being accepted by the sufferers and having vast social benefit and economic benefit.

Diet composition for use in the prevention and / or the treatment of endometrial hyperplasia in a human subject comprising a) a fasting mimicking diet component to be administered for a first period oftime and providing less than 50% of the normal caloric intake of the subject with both protein restriction and sugar restriction; and b) a re-feeding diet component to be administered for a second time period, which provides 60-100% of the normal caloric intake of the subject, wherein the fasting mimicking diet component and the re-feeding diet component are administered over multiple cycles.

The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and / or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.

The invention discloses small interfering RNA for suppressing vascular intimal hyperplasia. The nucleotide sequence of sense chain of the small interfering RNA is represented by sequence 1 in the sequence table, and the nucleotide sequence of antisense chain of the small interfering RNA is represented by sequence 2 in the sequence table. The small interfering RNA for suppressing vascular intimal hyperplasia can be directly applied to vascular adventitia to persistently and remarkably suppress vascular intimal hyperplasia, and can be used for treating restenosis after angioplasty.

The invention discloses a traditional Chinese medicine composition capable of treating menstrual flow and infertility caused by thin endometrium and a preparation method thereof. 1~6 parts, 1~9 parts of cornus, 1~6 parts of fried white peony, 0.5~3 parts of fried angelica, 1~9 parts of Chuanxiong, 1.5~9 parts of Suanzaoren, 1~9 parts of Anemarrhena, cloud Made from 1-6 parts of Poria cocos, 1-6 parts of fried Codonopsis pilosula, and 1-12 parts of fried Atractylodes macrocephala. The present invention screens and obtains the prescription through a large number of clinical studies, and the research results show that the Chinese medicine compound can effectively improve the symptoms of less menstrual flow and infertility of the kidney yin deficiency type, increase menstrual flow, and promote endometrial hyperplasia and follicular growth in the late menstrual period. Develop and improve serum E2 and LH levels during ovulation, improve E2 and P levels in the mid-luteal phase, increase the thickness of the endometrium in the mid-luteal phase, increase the volume of the endometrium, and enrich the subendometrial blood perfusion in the mid-luteal phase, thereby increasing the endometrial volume Receptivity, promote embryo implantation, and no toxic side effects, safe and reliable medication.